Anebulo Pharmaceuticals (FRA:214) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:214 Anebulo Pharmaceuticals Inc FRA:214
35 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:214
35GF Score
Anebulo Pharmaceuticals Inc FRA:214
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals Business Description

Other Exchanges ANEB:USA
Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for FRA:214

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price